A phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of golcadomide plus R-CHOP chemotherapy vs placebo plus R-CHOP chemotherapy in participants with previously untreated high-risk large B-cell lymphoma
B-cell lymphoma
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
TAN SUI KEAT
CONTACT
SC: Nur Awatif Akmal Muhamad Hata
A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab, an anti-CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B- cell Lymphoma (DLBCL) (OLYMPIA-3)
Diffuse Large B-cell Lymphoma
Tengku Ampuan Afzan Hospital, Kuantan
PRINCIPAL INVESTIGATOR
AHLAM NAILA BT KORI
CONTACT
SC: Fatma Diyana Mohd Bukhari
Genetic Variation Associated with Bortezomib Induced Peripheral Neuropathy in Adult Multiple Myeloma Patients (Investigator initiated study) (IMR Bortezomib)
Multiple Myeloma
Beacon Hospital
PRINCIPAL INVESTIGATOR
Dr Tengku Ahmad Hidayat
+603 7787 2993
drtengkuhidayat@gmail.com
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
Relapsed or Refractory Multiple Myeloma
Pulau Pinang Hospital
PRINCIPAL INVESTIGATOR
TAN SUI KEAT
CONTACT
SC: Siti Nurfazlina Binti Mohd Roslan
CRC: 042225767 / 762
A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)
Follicular Lymphoma and Marginal Zone Lymphoma
Ampang Hospital
PRINCIPAL INVESTIGATOR
TAN SEN MUI
tan.sen.mui@moh.gov.my
03-42896156
CONTACT
SC: NORFARAHIN BADRUL HISHAM
Sultanah Aminah Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Boo Yang Liang
CONTACT
SC: Rainianti Daman, Hafizah
CRC: 07 – 356 5000 ext: 2408
A phase 3, randomized, open label study evaluating the efficacy and safety of odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, versus standard of care therapy in participants with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (OLYMPIA-4)
B-cell non-Hodgkin lymphoma
Ampang Hospital
PRINCIPAL INVESTIGATOR
TAN SEN MUI
tan.sen.mui@moh.gov.my
03-42896156
CONTACT
SC: Wan Nor Atikah Binti Che Wan Mohd Rozali
Sultanah Aminah Hospital, Johor Bahru
PRINCIPAL INVESTIGATOR
Boo Yang Liang
CONTACT
SC: Komathy A/P Selvaraj
Queen Elizabeth Hospital
PRINCIPAL INVESTIGATOR
LILY WONG LEE LEE
CONTACT
SC: Merrin Suih